The TransQST consortium is pleased to announce the members of the TransQST Ethics Advisory Board (EAB) and the TransQST Scientific Advisory Board (SAB).
To achieve the TransQST objectives, the consortium will use pre-existing data wherever possible but will, on occasion, require access to human/animal biofluid samples and tissue biopsies in order to back-fill data gaps for model generation and validation. An Ethics Advisory Board has been formed to get advice on ethical questions associated with the use and generation of data in the framework of the project, and they are expected to submit an annual ethics report to be sent to the IMI office. The composition of the TransQST EAB is as follows:
2 selected members of the consortium with expertise in the field:
Susanne Rensing (AbbVie, preclinical data)
Mark Pritchard (University of Liverpool, clinical data)
1 independent external expert:
Jan Willem van der Laan (Safety Working Party at EMA, Pharmacology/Toxicology and Drug Regulation)
1 representative of the TransQST Executive Committee.
To cover assessment of several aspects related to the Systems Toxicology translational research, a Scientific Advisory Board has been formed by 4 independent experts with relevant expertise with consultative functions who can provide expert advice on the project progress, achievements and challenges. The composition of the TransQST SAB is as follows:
Chris Evelo (University of Maastricht)
Tim Hammond (Preclinical Safety Consulting Ltd)
Adriano Henney (Avicenna Alliance)
Nicolas Le Novère (Babraham Institute)
The SAB members key expertise in topics like Bioinformatics, Systems Biology, Networking Biology, Data interoperability platforms, Standards application/development (ontologies and data formats diversity), Databases (visual representation of model and data), Modelling and Simulation tools (chemical kinetics, QSP and multi-scale), Pharmacology, Virtual Liver Network and Cardiovascular diseases; will help the consortium members to achieve the goals of the project.